1.Pennell, PB. Hormonal aspects of epilepsy. Neurol Clin. 2009;27(4):941–965.
2.Penovich, PE. The effects of epilepsy and its treatment on sexual and reproductive function. Epilepsia. 2000;41(Suppl 2):S53–61.
3.Harden, CL, Pennell, PB. Neuroendocrine considerations in the treatment of men and women with epilepsy. Lancet Neurol. 2013;12(1):72–83.
4.Herzog, AG. Catamenial epilepsy: definition, prevalence pathophysiology and treatment. Seizure. 2008;17(2):151–159.
5.Herzog, AG, Klein, P, Ransil, BJ. Three patterns of catamenial epilepsy. Epilepsia. 1997;38(10):1082–1088.
6.Frederiksen, MC. Depot medroxyprogesterone acetate contraception in women with medical problems. J Reprod Med. 1996;41(5 Suppl):414–418.
7.Herzog, AG. Progesterone therapy in women with epilepsy: a 3-year follow-up. Neurology. 1999;52(9):1917–1918.
8.Herzog, AG. Progesterone therapy in women with complex partial and secondary generalized seizures. Neurology. 1995;45(9):1660–1662.
9.Herzog, AG. Clomiphene therapy in epileptic women with menstrual disorders. Neurology. 1988;38(3):432–434.
10.Herzog, AG, Fowler, KM, Smithson, SD, et al. Progesterone vs placebo therapy for women with epilepsy: a randomized clinical trial. Neurology. 2012;78(24):1959–1966.
11.Nohria, V, Giller, E. Ganaxolone. Neurotherapeutics. 2007;4(1):102–105.
12.Reddy, DS, Rogawski, MA. Neurosteroid replacement therapy for catamenial epilepsy. Neurotherapeutics. 2009;6(2):392–401.
13.Herzog, AG. Psychoneuroendocrine aspects of temporolimbic epilepsy. Part II: epilepsy and reproductive steroids. Psychosomatics. 1999;40(2):102–108.
14.Cummings, LN, Giudice, L, Morrell, MJ. Ovulatory function in epilepsy. Epilepsia. 1995;36(4):355–359.
15.Herzog, AG, Seibel, MM, Schomer, DL, Vaitukaitis, JL, Geschwind, N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol. 1986;43(4):341–346.
16.Herzog, AG, Schachter, SC. Valproate and the polycystic ovarian syndrome: final thoughts. Epilepsia. 2001;42(3):311–315.
17.Bilo, L, Meo, R, Nappi, C, et al. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia. 1988;29(5):612–619.
18.Knochenhauer, ES, Key, TJ, Kahsar-Miller, M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83(9):3078–3082.
19.Isojarvi, JI, Laatikainen, TJ, Pakarinen, AJ, Juntunen, KT, Myllyla, VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med. 1993;329(19):1383-1388.
20.Vainionpaa, LK, Rattya, J, Knip, M, et al. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol. 1999;45(4):444-450.
21.Isojarvi, JI, Tauboll, E, Tapanainen, JS, et al. On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia. 2001;42(3):305–310.
22.Isojarvi, JI, Laatikainen, TJ, Knip, M, et al. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol. 1996;39(5):579–584.
23.Lofgren, E, Mikkonen, K, Tolonen, U, et al. Reproductive endocrine function in women with epilepsy: the role of epilepsy type and medication. Epilepsy Behav. 2007;10(1):77–83.
24.Morrell, MJ, Hayes, FJ, Sluss, PM, et al. Hyperandrogenism, ovulatory dysfunction, and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol. 2008;64(2):200–211.
25.Isojarvi, JI, Rattya, J, Myllyla, VV, et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol. 1998;43(4):446–451.
26.Joffe, H, Cohen, LS, Suppes, T, et al. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry. 2006;59(11):1078–1086.
27.Cramer, JA, Gordon, J, Schachter, S, Devinsky, O. Women with epilepsy: hormonal issues from menarche through menopause. Epilepsy Behav. 2007;11(2):160–178.
28.Reimers, A, Brodtkorb, E, Sabers, A. Interactions between hormonal contraception and antiepileptic drugs: clinical and mechanistic considerations. Seizure. 2015;28:66–70.
29.Schupf, N, Ottman, R. Reproduction among individuals with idiopathic/cryptogenic epilepsy: risk factors for reduced fertility in marriage. Epilepsia. 1996;37(9):833–840.
30.Artama, M, Isojarvi, JI, Raitanen, J, Auvinen, A. Birth rate among patients with epilepsy: a nationwide population-based cohort study in Finland. Am J Epidemiol. 2004;159(11):1057–1063.
31.Lofgren, E, Pouta, A, von Wendt, L, et al. Epilepsy in the northern Finland birth cohort 1966 with special reference to fertility. Epilepsy Behav. 2009;14(1):102–107.
32.Olafsson, E, Hauser, WA, Gudmundsson, G. Fertility in patients with epilepsy: a population-based study. Neurology. 1998;51(1):71–73.
33.Agarwal, P, Mehndiratta, MM, Antony, AR, et al. Epilepsy in India: nuptiality behaviour and fertility. Seizure. 2006;15(6):409–415.
34.Sukumaran, SC, Sarma, PS, Thomas, SV. Polytherapy increases the risk of infertility in women with epilepsy. Neurology. 2010;75(15):1351–1355.
35.Harden, CL, Hopp, J, Ting, TY, et al. Practice parameter update. Management issues for women with epilepsy – focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73(2):126–132.
36.Pennell, PB, Meador, KJ, May, R, et al. Obstetric and neonatal outcomes in the MONEAD study [Abst. 1.217]. American Epilepsy Society 71st Annual Meeting; December 1-5, 2017; Washington, DC. 2017.
37.Meador, KJ, Pennell, PB, May, RC, et al. Miscarriages in pregnant women with epilepsy: findings from the MONEAD Study. 32nd International Epilepsy Congress; Barcelona, Spain. 2017.
38.MacDonald, SC, Bateman, BT, McElrath, TF, Hernandez-Diaz, S. Mortality and morbidity during delivery hospitalization among pregnant women with epilepsy in the United States. JAMA Neurol. 2015;72(9):981–988.
39.EURAP Study Group. Seizure control and treatment in pregnancy: observations from the EURAP epilepsy pregnancy registry. Neurology. 2006;66(3):354–360.
40.Nei, M, Daly, S, Liporace, J. A maternal complex partial seizure in labor can affect fetal heart rate. Neurology. 1998;51(3):904–906.
41.Ramus, RM, Cantrell, DC, Cunningham, FG, Leveno, K, Riela, AR. Effects of partial seizures on the infants of women with epilepsy [abstract]. Epilepsia. 1997;38(S8):230.
42.Teramo, K, Hiilesmaa, V, Bardy, A, Saarikoski, S. Fetal heart rate during a maternal grand mal epileptic seizure. J Perinat Med. 1979;7(1):3–6.
43.Chen, YH, Chiou, HY, Lin, HC, Lin, HL. Effect of seizures during gestation on pregnancy outcomes in women with epilepsy. Arch Neurol. 2009;66(8):979–984.
44.Hovinga, CA, Pennell, PB. Antiepileptic drug therapy in pregnancy II: fetal and neonatal exposure. Int Rev Neurobiol. 2008;83:241–258.
45.Meador, KJ, Pennell, PB, Harden, CL, et al. Pregnancy registries in epilepsy: a consensus statement on health outcomes. Neurology. 2008;71(14):1109–1117.
46.Artama, M, Auvinen, A, Raudaskoski, T, Isojarvi, I, Isojarvi, J. Antiepileptic drug use of women with epilepsy and congenital malformations in offspring. Neurology. 2005;64(11):1874–1878.
47.Morrow, J, Russell, A, Guthrie, E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry. 2006;77(2):193–198.
48.Tomson, T, Battino, D, Bonizzoni, E, et al. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol. 2011;10(7):609–617.
49.North American Antiepileptic Drug Pregnancy Registry. Update on montherapy findings: comparative safety of 11 antiepileptic drugs used during pregnancy. North American Antiepileptic Drug Pregnancy Registry Newsletter. 2016;Winter 2016:1–2.
50.Campbell, E, Kennedy, F, Russell, A, et al. Malformation risks of antiepileptic drug monotherapies in pregnancy: updated results from the UK and Ireland Epilepsy and Pregnancy Registers. J Neurol Neurosurg Psychiatry. 2014;85(9):1029–1034.
51.Meador, KJ, Baker, GA, Finnell, RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology. 2006;67(3):407–412.
52.Holmes, LB, Wyszynski, DF, Baldwin, EJ, et al. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy [abstract]. Birth Defects Res Part A Clin Mol Teratol. 2006;76(5):318.
53.EUROCAT Antiepileptic Drug Working Group: Dolk, H, Jentink, J, Loane, M, Morris, J, de Jong-van den Berg, LT. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology. 2008;71(10):714–722.
54.Hunt, S, Russell, A, Smithson, WH, et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology. 2008;71(4):272–276.
55.Green, MW, Seeger, JD, Peterson, C, Bhattacharyya, A. Utilization of topiramate during pregnancy and risk of birth defects. Headache. 2012;52(7):1070–1084.
56.Margulis, AV, Mitchell, AA, Gilboa, SM, et al. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol. 2012;207(5):405.e1–7.
57.Jentink, J, Loane, MA, Dolk, H, et al. Valproic acid monotherapy in pregnancy and major congenital malformations. N Engl J Med. 2010;362(23):2185–2193.
58.Moore, SJ, Turnpenny, P, Quinn, A, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet. 2000;37(7):489–497.
59.Veiby, G, Daltveit, AK, Engelsen, BA, Gilhus, NE. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol. 2014;261(3):579–588.
60.Hernandez-Diaz, S, Mittendorf, R, Smith, CR, et al. Association between topiramate and zonisamide use during pregnancy and low birth weight. Obstet Gynecol. 2014;123(1):21–28.
61.Johnston, M, Landers, S, Noble, L, Szucs, K, Viehmann, L; Section on Breastfeeding. Breastfeeding and the use of human milk. Pediatrics. 2012;129(3):e827–841.
62.Harden, CL, Pennell, PB, Koppel, BS, et al. Practice parameter update. Management issues for women with epilepsy – focus on pregnancy (an evidence-based review). Vitamin K, folic acid, blood levels, and breastfeeding: report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73(2):142–149.
63.Tomson, T. Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. Ther Drug Monit. 2005;27(6):718–721.
65.Liporace, J, Kao, A, D’Abreu, A. Concerns regarding lamotrigine and breast-feeding. Epilepsy Behav. 2004;5(1):102–105.
66.Newport, DJ, Pennell, PB, Calamaras, MR, et al. Lamotrigine in breast milk and nursing infants: determination of exposure. Pediatrics. 2008;122(1):e223–231.
67.Veiby, G, Bjork, M, Engelsen, BA, Gilhus, NE. Epilepsy and recommendations for breastfeeding. Seizure. 2015;28:57–65.
68.Veiby, G, Engelsen, BA, Gilhus, NE. Early child development and exposure to antiepileptic drugs prenatally and through breastfeeding: a prospective cohort study on children of women with epilepsy. JAMA Neurol. 2013;70(11):1367–1374.
69.Meador, KJ, Baker, GA, Browning, N, et al. Breastfeeding in children of women taking antiepileptic drugs: cognitive outcomes at age 6 years. JAMA Pediatr. 2014;168(8):729–736.
70.Kim, J, Kondratyev, A, Gale, K. Antiepileptic drug-induced neuronal cell death in the immature brain: effects of carbamazepine, topiramate, and levetiracetam as monotherapy versus polytherapy. J Pharmacol Exp Ther. 2007;323(1):165–173.
71.Meador, KJ, Baker, G, Cohen, MJ, Gaily, E, Westerveld, M. Cognitive/behavioral teratogenetic effects of antiepileptic drugs. Epilepsy Behav. 2007;11(3):292–302.
72.Veiby, G, Daltveit, AK, Schjolberg, S, et al. Exposure to antiepileptic drugs in utero and child development: a prospective population-based study. Epilepsia. 2013;54(8):1462–1472.
73.Meador, KJ, Baker, GA, Browning, N, et al. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain. 2011;134(Pt 2):396–404.
74.Meador, KJ, Baker, GA, Browning, N, et al. Fetal antiepileptic drug exposure and cognitive outcomes at age 6 years (NEAD study): a prospective observational study. Lancet Neurol. 2013;12(3):244–252.
75.Titze, K, Koch, S, Helge, H, et al. Prenatal and family risks of children born to mothers with epilepsy: effects on cognitive development. Dev Med Child Neurol. 2008;50(2):117–122.
76.Bromley, RL, Mawer, GE, Briggs, M, et al. The prevalence of neurodevelopmental disorders in children prenatally exposed to antiepileptic drugs. J Neurol Neurosurg Psychiatry. 2013;84(6):637–643.
77.Thomas, SV, Ajaykumar, B, Sindhu, K, et al. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav. 2008;13(1):229–236.
78.Veroniki, AA, Rios, P, Cogo, E, et al. Comparative safety of antiepileptic drugs for neurological development in children exposed during pregnancy and breast feeding: a systematic review and network meta-analysis. BMJ Open. 2017;7(7):e017248.
79.Kantola-Sorsa, E, Gaily, E, Isoaho, M, Korkman, M. Neuropsychological outcomes in children of mothers with epilepsy. J Int Neuropsychol Soc. 2007;13(4):642–652.
80.Viinikainen, K, Eriksson, K, Monkkonen, A, et al. The effects of valproate exposure in utero on behavior and the need for educational support in school-aged children. Epilepsy Behav. 2006;9(4):636–640.
81.Thomas, SV, Sukumaran, S, Lukose, N, George, A, Sarma, PS. Intellectual and language functions in children of mothers with epilepsy. Epilepsia. 2007;48(12):2234–2240.
84.Kogan, MD, Blumberg, SJ, Schieve, LA, et al. Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007. Pediatrics. 2009;124(5):1395–1403.
85.Autism and Developmental Disabilities Monitoring Network Surveillance Year 2006 Principal Investigators, Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders – Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ. 2009;58(10):1–20.
86.Christensen, J, Gronborg, TK, Sorensen, MJ, et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA. 2013;309(16):1696–1703.
87.Rasalam, AD, Hailey, H, Williams, JH, et al. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol. 2005;47(8):551–555.
88.Harden, CL, Pulver, MC, Ravdin, L, Jacobs, AR. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia. 1999;40(10):1402–1407.
89.Pennell, PB. More is not better: hormones for menopausal women with epilepsy? Epilepsy Curr. 2007;7(3):68–70.
90.Harden, CL, Koppel, BS, Herzog, AG, Nikolov, BG, Hauser, WA. Seizure frequency is associated with age at menopause in women with epilepsy. Neurology. 2003;61(4):451–455.
91.Serje, A, Klein, P. Premature ovarian failure in women with epilepsy [abstract]. Epilepsia. 2000;41(Suppl 7):198.
92.Tran, TA. B.01 Premature ovarian failure in women with epilepsy [abstract]. Epilepsia. 2006;47(S4):7.
93.Winters, SJ, Janick, JJ, Loriaux, DL, Sherins, RJ. Studies on the role of sex steroids in the feedback control of gonadotropin concentrations in men. II. Use of the estrogen antagonist, clomiphene citrate. J Clin Endocrinol Metab. 1979;48(2):222–227.
94.Reddy, DS. Testosterone modulation of seizure susceptibility is mediated by neurosteroids 3alpha-androstanediol and 17beta-estradiol. Neuroscience. 2004;129(1):195–207.
95.Toone, BK, Wheeler, M, Nanjee, M, Fenwick, P, Grant, R. Sex hormones, sexual activity and plasma anticonvulsant levels in male epileptics. J Neurol Neurosurg Psychiatry. 1983;46(9):824–826.
96.Rodin, E, Subramanian, MG, Gilroy, J. Investigation of sex hormones in male epileptic patients. Epilepsia. 1984;25(6):690–694.
97.Isojarvi, JI, Repo, M, Pakarinen, AJ, Lukkarinen, O, Myllyla, VV. Carbamazepine, phenytoin, sex hormones, and sexual function in men with epilepsy. Epilepsia. 1995;36(4):366–370.
98.Duncan, S, Blacklaw, J, Beastall, GH, Brodie, MJ. Antiepileptic drug therapy and sexual function in men with epilepsy. Epilepsia. 1999;40(2):197–204.
99.Herzog, AG, Drislane, FW, Schomer, DL, et al. Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy. Neurology. 2005;65(7):1016–1020.
100.Isojarvi, JI, Pakarinen, AJ, Rautio, A, Pelkonen, O, Myllyla, VV. Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. Eur J Clin Pharmacol. 1995;47(5):461–464.
101.Bauer, J, Stoffel-Wagner, B, Flugel, D, et al. Serum androgens return to normal after temporal lobe epilepsy surgery in men. Neurology. 2000;55(6):820–824.
102.Bauer, J, Blumenthal, S, Reuber, M, Stoffel-Wagner, B. Epilepsy syndrome, focus location, and treatment choice affect testicular function in men with epilepsy. Neurology. 2004;62(2):243–246.
103.Hellmis, E. Sexual problems in males with epilepsy – an interdisciplinary challenge! Seizure. 2008;17(2):136–140.
104.Guldner, GT, Morrell, MJ. Nocturnal penile tumescence and rigidity evaluation in men with epilepsy. Epilepsia. 1996;37(12):1211–1214.
105.Talbot, JA, Sheldrick, R, Caswell, H, Duncan, S. Sexual function in men with epilepsy: how important is testosterone? Neurology. 2008;70(16):1346–1352.
106.Isojarvi, JI, Lofgren, E, Juntunen, KS, et al. Effect of epilepsy and antiepileptic drugs on male reproductive health. Neurology. 2004;62(2):247–253.
107.Isidori, AM, Giannetta, E, Gianfrilli, D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf). 2005;63(4):381–394.
108.Harden, CL, Meador, KJ, Pennell, PB, et al. Practice parameter update. Management issues for women with epilepsy – focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes. Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology. 2009;73(2):133–141.